T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1826
Timken Company
TKR
$9.03B
| $686K | ﹤0.01% |
22,386
| – | – |
|
1827
Apogee Enterprises
APOG
$897M
| $685K | ﹤0.01% |
14,780
-222,590
| -94% | -$9.67M |
|
1828
Granite Construction
GVA
$5.41B
| $681K | ﹤0.01% |
14,950
| – | – |
|
|
QTS
1829
DELISTED
QTS REALTY TRUST, INC.
QTS
| $680K | ﹤0.01% |
12,146
+1,576
| +15% | +$81.2K |
|
1830
NBT Bancorp
NBTB
$2.78B
| $679K | ﹤0.01% |
23,700
| – | – |
|
1831
Greif
GEF
$5.03B
| $678K | ﹤0.01% |
18,180
+2,800
| +18% | +$100K |
|
1832
Sinclair Inc
SBGI
$1B
| $674K | ﹤0.01% |
22,580
-5,700
| -20% | -$178K |
|
1833
Northwest Natural Holdings
NWN
$2.12B
| $672K | ﹤0.01% |
10,370
| – | – |
|
|
BPFH
1834
DELISTED
Boston Private Financial Holdings, Inc.
BPFH
| $670K | ﹤0.01% |
56,849
+2,727
| +5% | +$32.8K |
|
|
SNBR
1835
DELISTED
Sleep Number
SNBR
| $669K | ﹤0.01% |
31,280
+3,500
| +13% | +$76.3K |
|
|
NTRI
1836
DELISTED
NutriSystem, Inc.
NTRI
| $669K | ﹤0.01% |
26,391
+4,191
| +19% | +$101K |
|
|
WCC
1837
WESCO International
WCC
$17.8B
| $667K | ﹤0.01% |
12,948
-611
| -5% | -$34.4K |
|
1838
Cathay General Bancorp
CATY
$4.31B
| $662K | ﹤0.01% |
23,466
| – | – |
|
1839
LiveRamp
RAMP
$2.3B
| $662K | ﹤0.01% |
30,100
| – | – |
|
|
TIVO
1840
DELISTED
Tivo Inc
TIVO
| $662K | ﹤0.01% |
42,343
| – | – |
|
1841
Hyatt Hotels
H
$16.8B
| $661K | ﹤0.01% |
13,455
-13
| -0.1% | -$621 |
|
1842
Invesco Mortgage Capital
IVR
$805M
| $661K | ﹤0.01% |
4,830
+770
| +19% | +$104K |
|
|
BSFT
1843
DELISTED
BroadSoft, Inc.
BSFT
| $656K | ﹤0.01% |
15,980
| – | – |
|
1844
Asbury Automotive
ABG
$3.76B
| $649K | ﹤0.01% |
12,302
-8
| -0.1% | -$449 |
|
|
PETX
1845
DELISTED
Aratana Therapeutics, Inc.
PETX
| $648K | ﹤0.01% |
102,601
| – | – |
|
|
EFOR
1846
Everforth Inc
EFOR
$1.34B
| $646K | ﹤0.01% |
17,480
| – | – |
|
1847
Forward Air
FWRD
$658M
| $646K | ﹤0.01% |
14,515
| – | – |
|
|
ACH
1848
Accendra Health
ACH
$84.6M
| $646K | ﹤0.01% |
17,295
+535
| +3% | +$20.1K |
|
|
BCPC
1849
Balchem Corp
BCPC
$5.65B
| $646K | ﹤0.01% |
10,830
-700
| -6% | -$42.8K |
|
|
AGR
1850
DELISTED
Avangrid, Inc.
AGR
| $646K | ﹤0.01% |
+14,020
| New | +$578K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.